Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), IDIS Research Institute, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.
Department of Pharmacology, Pharmacy and Pharmaceutical Technology, School of Pharmacy, Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.
Tissue Eng Part B Rev. 2021 Apr;27(2):133-154. doi: 10.1089/ten.TEB.2020.0096. Epub 2020 Aug 26.
Human meniscus is a fibrocartilaginous structure that is crucial for an adequate performance of the human knee joint. Degeneration of the meniscus is often followed by partial or total meniscectomy, which enhances the risk of developing knee osteoarthritis. The lack of a satisfactory treatment for this condition has triggered a major interest in drug delivery (DD) and tissue engineering (TE) strategies intended to restore a bioactive and fully functional meniscal tissue. The aim of this review is to critically discuss the most relevant studies on spatiotemporal DD and TE, aiming for a multizonal meniscal reconstruction. Indeed, the development of meniscal tissue implants should involve a provision for adequate active molecules and scaffold features that take into account the anisotropic ultrastructure of human meniscus. This zonal differentiation is reflected in the meniscus biochemical composition, collagen fiber arrangement, and cell distribution. In this sense, it is expected that a proper combination of advanced DD and zonal TE strategies will play a key role in the future trends in meniscus regeneration. Impact statement Meniscus degeneration is one of the main causes of knee pain, inflammation, and reduced mobility. Currently used suturing procedures and meniscectomy are far from being ideal solutions to the loss of meniscal function. Therefore, drug delivery (DD) and tissue engineering (TE) strategies are currently under investigation. DD systems aim at an controlled release of growth factors, whereas TE strategies aim at mimicking the anisotropy of native meniscus. The goal of this review is to discuss these two main approaches, as well as synergies between them that are expected to lead to a real breakthrough in the field.
人类半月板是一种纤维软骨结构,对于人类膝关节的正常功能至关重要。半月板的退化常伴随着部分或全部半月板切除术,这增加了发展为膝关节骨关节炎的风险。由于缺乏对此类疾病的满意治疗方法,人们对药物输送 (DD) 和组织工程 (TE) 策略产生了极大的兴趣,旨在恢复具有生物活性和完全功能的半月板组织。本文的目的是批判性地讨论关于时空 DD 和 TE 的最相关研究,旨在实现多区域半月板重建。事实上,半月板组织植入物的开发应包括提供足够的活性分子和支架特性,以考虑到人类半月板的各向异性超微结构。这种分区分化反映在半月板的生化组成、胶原纤维排列和细胞分布上。从这个意义上说,预计先进的 DD 和分区 TE 策略的恰当结合将在未来的半月板再生趋势中发挥关键作用。
声明:半月板退化是膝关节疼痛、炎症和活动能力下降的主要原因之一。目前使用的缝合程序和半月板切除术远非丧失半月板功能的理想解决方案。因此,药物输送 (DD) 和组织工程 (TE) 策略正在研究中。DD 系统旨在控制生长因子的释放,而 TE 策略旨在模拟天然半月板的各向异性。本文的目的是讨论这两种主要方法,以及它们之间的协同作用,预计这将在该领域取得真正的突破。